AbCellera Biologics Inc. reported an insider ownership change for Lynn Seely on a Form 4 filed July 6, 2026, covering a transaction dated July 1, 2026. The filing concerns derivative securities, and the explanatory note indicates the action involved a stock option award. According to the filing text, the shares underlying the option “vest and become exercisable annually in substantially equal installments over a three-year period.” The first tranche is scheduled to vest on July 1, 2027, provided Seely remains in continuous service to AbCellera on each applicable vesting date. That structure suggests a service-based equity compensation grant rather than an open-market purchase or sale. The excerpt provided does not disclose the number of option shares granted, the exercise price, the transaction code, or the number of derivative securities beneficially owned after the transaction. It also does not show any reported disposition or acquisition of AbCellera common shares in the non-derivative securities table. The only concrete transaction detail available is the July 1, 2026 option-related ownership change and its three-year annual vesting schedule. The Form 4 was signed on Seely’s behalf by Tryn Stimart, attorney-in-fact, on July 6, 2026. The filing matters because it reports equity-based compensation or ownership changes by an insider, which investors often monitor to understand alignment between company leadership and shareholders, even when the filing reflects routine compensation rather than a market transaction.